As 6th case of measles found in province, Sask. health authority urges vaccination
The Saskatchewan Health Authority (SHA) is reporting a sixth case of measles in the province.
The latest case is an adult in southwest Saskatchewan who recently traveled through the U.S. and Mexico. They were not immunized for the disease.
To date, there have been three confirmed measles cases in the southwest of the province, two in the southeast and one in the northwest.
While the number of confirmed measles cases in Saskatchewan is still much lower than other provinces like Alberta and Ontario, the SHA is still warning the public of the threat it poses, and is strongly encouraging residents to get vaccinated for the disease.
"It is extremely contagious. It doesn't take much for it to be spread to other folks," said Dr. David Torr, a health officer with the SHA.
"It's not like influenza where it's just droplets or even with COVID, measles just is very, very easily transmissible through the air."
Measles can also be transmitted through a person touching their face after contacting a contaminated surface, where it can survive for up to two hours after contact.
Symptoms of the measles virus include fever, coughing and a runny nose. As the disease develops in the body, small white spots may appear inside the mouth and throat. About three to seven days after symptoms begin, a red blotchy rash can develop on the victim's face.
There is no known cure for measles, but Dr. Torr emphasized the effectiveness of the vaccine, which is readily available. The key to stopping the spread of the virus, he said, was reaching a critical mass of vaccinated people.
"If we had 95% across the board of immunization, we would have extremely good herd immunity," he said. "But we have such a variation, depending on which area or which little small geography you look at that varies anything from 40, 50, 60, 80 per cent."
Schools are not requiring students to be vaccinated to attend, but the SHA is strongly encouraging students to get vaccinated. It provides the vaccine free of charge to Saskatchewan residents who were not vaccinated as children. Residents unsure of their vaccination status can check it by visiting MySaskHealthRecord.
The SHA is advising residents that if they have symptoms of measles or need measles testing, they should not visit a clinic or hospital. Instead, they should call HealthLine 811 for instructions and guidance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Forward
15 hours ago
- Japan Forward
AI Tool 'KIBIT': A Game Changer in New Drug Development
このページを 日本語 で読む The COVID-19 pandemic reminded the world of the importance of drug discovery. However, modern drug discoveries require massive financial investment. Meanwhile, the use of artificial intelligence for AI drug discovery is gaining attention as a way to control soaring pharmaceutical prices. And a Japanese-made AI tool named 'KIBIT' is about to open up a new stage in this field. President Donald Trump issued executive orders in April and May mandating the reduction of domestic drug prices in the United States. Accompanying White House fact sheets refer to the high cost Americans pay for prescriptions, which is 2.78 times higher than the OECD average. Prescription costs are also 3.47 times higher than in Japan. Trump sees these high costs to consumers as a serious issue. In Japan, a national drug pricing system sets medication prices, enabling access to affordable treatments due to governmental oversight. In contrast, US pharmaceutical companies can set prices freely. This often results in higher charges than in other countries. Following his May 12 executive order, Trump stated that his orders would cut prices by 59% to as much as 90% to align with the levels of other countries. This could potentially result in significant revenue losses for the pharmaceutical industry. In the case of Japan, major pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Astellas Pharma Inc earn over 30% of their revenue from the US. According to his comments, the President could impose additional tariffs on foreign-manufactured drugs if prices are not reduced. In the search for new drugs and treatments (Screenshot, ©FRONTEO Inc) One major reason for rising drug prices is the increasing cost of research and development. The average R&D spending by Japanese pharmaceutical companies rose from ¥30.2 billion JPY ($298.7 million USD) in 1993 to 163.3 billion ($1.13 billion) in 2019 — a 5.4-fold increase over 26 years. US companies saw an even sharper rise, from $841 million (¥121.1 billion) to $7.449 billion (¥1.0725 trillion). That marked an 8.8-fold increase. Moreover, investing in R&D doesn't guarantee success. The probability of developing a successful drug in Japan dropped from 1 in 13,000 two decades ago to 1 in 23,000 recently. Despite the increasing costs, results are scarce. Consequently, the R&D-to-revenue ratio rose from about 10% in 1993 to around 18% in 2019 in both countries. Introducing KIBIT. (Screenshot ©FRONTEO Inc) AI is being eyed as a solution to reduce R&D costs by dramatically cutting time and expenses. Drug development involves four stages: Basic research & target identification Compound optimization Preclinical trials and Clinical trials. Many AI vendors are involved in drug discovery. In particular, they focus on reducing costs in the third (preclinical) and fourth (clinical) stages. However, most companies have yet to tackle the critical first stage — target identification. Introducing KIBIT. (Screenshot, ©FRONTEO Inc) The first enterprise to address this initial stage is the Japanese company FRONTEO. Utilizing its proprietary natural language processing AI engine KIBIT, the company analyzes vast medical and pharmaceutical literature to generate innovative drug ideas that researchers may not have considered. Human thinking is inherently biased. The more experienced a researcher is, the more difficult it becomes to identify novel molecular targets. Stated another way, the bias of experience often blocks new ideas. KIBIT, however, is free from such biases. It identifies new molecular targets that might be effective against specific diseases. To do so, it analyzes vast amounts of academic literature. It can even derive specific hypotheses. Furthermore, KIBIT can identify and suggest highly disease-relevant target molecules that are not explicitly mentioned in the literature. This significantly enhances drug discovery potential. How KIBIT works. (Screenshot, ©FRONTEO Inc) Only a few countries have the capacity to develop new drugs. In 2024, among newly approved pharmaceuticals in Japan, the US, and Europe, the US led with 143 products. Japan followed with just 12, roughly equal to the United Kingdom's 10. According to the statistics "Nationalities of companies creating the top 100 drugs in the world by sales (2022),": United States – 52 United Kingdom – 10 Switzerland – 9 Germany – 8 Denmark – 8 Japan – 7 Most countries, other than the US, struggle to produce blockbuster drugs. In this context, hopes are high for FRONTEO's KIBIT. If it can consistently generate innovative new drugs efficiently, it may help deliver affordable medicines to those in need, without Mr Trump's intervention. FRONTEO's AI drug discovery service, utilizing KIBIT, is already being adopted by several major pharmaceutical companies. Those leveraging KIBIT to create new drugs could become game changers in the industry. This article is contributed by FRONTEO Inc, a supporting member of JAPAN Forward. (Read the report in Japanese.) Author: FRONTEO Inc. このページを 日本語 で読む
Global News
2 days ago
- Global News
RFK Jr. removes all 17 members of U.S. vaccine advisory panel
U.S. Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the Centers for Disease Control and Prevention on how to use vaccines and pledged to replace them with his own picks. Major physicians and public health groups criticized the move to oust all 17 members of the Advisory Committee on Immunization Practices. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, has not said who he would appoint to the panel, but said it would convene in just two weeks in Atlanta. Although it's typically not viewed as a partisan board, the Biden administration had installed the entire committee. 'Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028,' Kennedy wrote in a Wall Street Journal opinion piece. 'A clean sweep is needed to re-establish public confidence in vaccine science.' Story continues below advertisement Kennedy said the committee members had too many conflicts of interest. Committee members routinely disclose any possible conflicts at the start of public meetings. Dr. Georges Benjamin, executive director of the American Public Health Association, called Kennedy's mass ouster 'a coup.' 'It's not how democracies work. It's not good for the health of the nation,' Benjamin told The Associated Press. 0:37 RFK announces COVID vaccine removal from immunization schedule for pregnant women and children Benjamin said the move raises real concerns about whether future committee members will be viewed as impartial. He added that Kennedy is going against what he told lawmakers and the public, and the public health association plans to watch Kennedy 'like a hawk.' Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'He is breaking a promise,' Benjamin said. 'He said he wasn't going to do this.' Dr. Bruce A. Scott, president of the American Medical Association, called the committee a trusted source of science- and data-driven advice and said Kennedy's move, coupled with declining vaccination rates across the country, will help drive an increase in vaccine-preventable diseases. Story continues below advertisement 'Today's action to remove the 17 sitting members of ACIP undermines that trust and upends a transparent process that has saved countless lives,' Scott said in a statement. Republican Sen. Bill Cassidy of Louisiana, a doctor who had expressed reservations about Kennedy's nomination but voted to install him as the nation's health secretary nonetheless, said he had spoken with Kennedy moments after the announcement. 'Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion,' Cassidy said in a social media post. 'I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case.' 9:34 RFK Jr. and Elizabeth Warren get into heated debate over vaccine question at confirmation hearing The committee had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. Story continues below advertisement During Kennedy's confirmation, Cassidy had expressed concerns about preserving the committee, saying he had sought assurances that Kennedy would keep the panel's current vaccine recommendations. Kennedy did not stick to that. He recently took the unusual step of changing COVID-19 recommendations without first consulting the advisers. The webpage that featured the committee's members was deleted Monday evening, shortly after Kennedy's announcement.
Winnipeg Free Press
2 days ago
- Winnipeg Free Press
RFK Jr. ousts entire CDC vaccine advisory committee
WASHINGTON (AP) — Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the Centers for Disease Control and Prevention on how to use vaccines and pledged to replace them with his own picks. The 17-member Advisory Committee on Immunization Practices had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, recently took the unusual step of changing COVID-19 recommendations without first consulting the panel. Kennedy, in a Wall Street Journal opinion piece, said the committee members had too many conflicts of interest. Committee members routinely disclose any possible conflicts at the start of public meetings. Wednesdays Columnist Jen Zoratti looks at what's next in arts, life and pop culture. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
